Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance

Ensysce Biosciences, Inc.

2024-Q2 EPS reported -$0.67 revenue$487,519

Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.
Cash and cash equivalents totaled $1.0M at June 30, 2024, down from $1.1M at year-end 2023.
R&D expense fell to $0.9M from $1.6M YoY, driven by lower clinical and pre-clinical costs.
PF614-MPAR Phase 1b study (PF614-MPAR-102) progressing with Quotient Sciences; overdose protection verification planned.
PF9001 selected as lead OUD candidate in June; supported by NIH/NIDA HEAL award up to $15M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.